



Lifestyle and anxiety disorders: BDNF, a possible biomarker?

Estilo de vida e transtornos de ansiedade: BDNF, possível biomarcador?

Estilo de vida y trastornos de ansiedad: ¿ BDNF, posible biomarcador?

Tatiana Marins Farias Farias



[ORCID](#) - [Lattes](#)

Sílvia Fernanda Lima de Moura Cal - [ORCID](#) - [Lattes](#)

Rebeca Ataíde de Cerqueira - [Lattes](#)

Ana Carolina Tavares Lopes - [ORCID](#) - [Lattes](#)

Danton Ferraz de Sousa - [ORCID](#) - [Lattes](#)

João Vitor Costa Freire - [ORCID](#) - [Lattes](#)

Ana Julia Bernardo - [ORCID](#) - [Lattes](#)

ABSTRACT:

Introduction: Anxiety disorders (AD) are brain disturbances related to neurotransmitter circuits and neuroanatomic changes that are aggravated by unhealthy lifestyle. In turn, the brain derived neurotrophic factor (BDNF), a neurotrophin responsible for cerebral plasticity, is related to alteration volume in some brain structures and it can be explained by some lifestyle factors. **Objective:** to analyze the relationship between BDNF and AD and describe possible damage to the psychic functions in individuals with these disorders. **Method:** this was an integrative review of the literature of articles published between 2008 and 2018, selected in the bibliographic databases of [PubMed](#), [SciELO](#) and [LILACS](#). **Results:** In total, 28 articles were selected, of studies conducted with humans and animals. The relationship between levels of BDNF, and AD was observed to have been approached, showing that the neurotrophic hypothesis could contribute to the physiopathology of ADs, including volumetric changes in regions of the brain, comprising psychic functions. Furthermore, studies have shown that the BDNF levels may reflect the effect of antidepressant

or neuromodulation therapy, and that exposure to stressful factors may be related to individuals with this genetic variant being more vulnerable to developing AD. **Conclusions:** The data obtained in this research pointed towards an inverse relationship between BDNF levels and AD, and to the contribution of the neurotrophic hypothesis to the neurobiology of these disturbances, including damage to the psychic functions. Whereas considering that other studies do not show this relationship, further studies need to be conducted to validate a possible association.

Keywords: BDNF, Brain-Derived Neurotrophic Factor, anxiety, anxiety disorders, neurobiology, lifestyle, review.

RESUMO:

Introdução: Os transtornos de ansiedade (TA) são distúrbios cerebrais relacionados aos circuitos de neurotransmissores e alterações neuroanatômicas que podem ser agravados pelo estilo de vida não saudável. Por sua vez, o fator neurotrófico derivado do cérebro (BDNF), uma neurotrofina responsável pela plasticidade cerebral, está relacionado à alteração do volume em algumas estruturas cerebrais e pode ser explicado por alguns fatores do estilo de vida. **Objetivo:** Analisar a relação entre BDNF e TA e descrever possíveis prejuízos às funções psíquicas em indivíduos com esses transtornos. **Método:** trata-se de uma revisão integrativa da literatura de artigos publicados entre 2008 e 2018, selecionados nas bases de dados bibliográficas [PubMed](#), [SciELO](#) e [LILACS](#). **Resultados:** No total, foram selecionados 28 artigos de estudos realizados com humanos e animais. Observou-se que a relação entre níveis de BDNF e TA foi abordada, mostrando que a hipótese neurotrófica poderia contribuir para a fisiopatologia das TAs, incluindo alterações volumétricas em regiões do cérebro, compreendendo funções psíquicas. Além disso, estudos demonstraram que os níveis de BDNF podem refletir o efeito de antidepressivos ou terapia de neuromodulação, e que a exposição a fatores estressantes pode estar relacionada a indivíduos com essa variante genética serem mais vulneráveis ao desenvolvimento de TA. **Conclusão:** Os dados obtidos nesta pesquisa apontaram para uma relação inversa entre os níveis de BDNF e TA, e para a contribuição da hipótese neurotrófica para a neurobiologia desses distúrbios, incluindo danos às funções psíquicas. Considerando que outros estudos não mostram essa relação, novos estudos precisam ser realizados para validar uma possível associação.

Palavras-chave: BDNF, fator neurotrófico derivado do encéfalo, ansiedade, transtornos de ansiedade, neurobiologia, estilo de vida, revisão.

RESUMEN:

Introducción: Los trastornos de ansiedad (TA) están asociados con alteraciones cerebrales relacionadas con neurotransmisores y cambios neuroanatómicos, agravados por un estilo de vida poco saludable. El factor neurotrófico derivado del cerebro (BDNF), que influye en la plasticidad cerebral, puede relacionarse con cambios en el volumen de estructuras cerebrales. **Objetivo:** El estudio busca analizar la conexión entre BDNF y los TA, así como describir las posibles consecuencias negativas en las funciones psicológicas de quienes padecen estos trastornos. **Método:** Se revisaron estudios publicados entre 2008 y 2018 en [PubMed](#), [SciELO](#) y [LILACS](#). **Resultados:** Se incluyeron 28 artículos que investigaron tanto en humanos como en animales. Estos estudios exploraron la relación entre los niveles de BDNF y los TA, sugiriendo que la hipótesis neurotrófica podría contribuir a comprender la fisiopatología de los TA, incluyendo cambios en regiones cerebrales relacionadas con funciones psicológicas. Además, se encontró que los niveles de BDNF podrían reflejar el impacto de tratamientos antidepresivos o de neuromodulación, y que la exposición a factores estresantes podría aumentar la vulnerabilidad a TA en personas con ciertas variantes genéticas. **Conclusión:** En resumen, los resultados sugieren una posible relación inversa entre los niveles de BDNF y los TA, destacando la importancia de la hipótesis neurotrófica en la neurobiología de estos trastornos y su influencia en las funciones psicológicas. Sin embargo, se necesita más investigación para validar esta asociación en su totalidad.

Palabras clave: BDNF, factor neurotrófico derivado del encéfalo, ansiedade, transtornos de ansiedade, neurobiología, estilo de vida, revisión.

Como citar: Farias TM, Cal SFLM, Cerqueira RA, Lopes ACT, Sousa DF, Freire JVC, Bernardo AJ. Lifestyle and anxiety disorder: BDNF, a possible biomarker? Brazilian Journal of Lifestyle Medicine = Revista Brasileira de Medicina do Estilo de Vida, São Paulo. 2023;1:1-36.

<https://doi.org/10.xxxxx/bjlm.2023.v1.69>



Conflito de interesses: declaram não haver

Fonte de financiamento: FUNADESP (Fundação Nacional para o Desenvolvimento do Ensino Particular) - National Foundation for the Development of Private Schooling

Parecer CEP: não se aplica

Recebido em: 23/09/2023

Aprovado em: 11/10/2023

Publicado em: 16/10/2023

Editor Chefe responsável pelo artigo: Nancy Huang

Contribuição dos autores segundo a [Taxonomia CRediT](#): Farias TM [1, 2, 3, 4, 5, 6, 7, 10, 12, 13, 14], Cal SFLM [2,3,5,6,7,10,13,14], Cerqueira RA e Lopes ACT [1, 2, 3, 5, 6, 9, 13, 14.], Sousa DF [1 e 14], Freire JVC [1, 5, 13 e 14], Bernardo AJ [13,14]

Introduction

Anxiety disorders (AD) have specific criteria, according to the Diagnostic and Statistical Manual of Mental Disorders (DSM V) [1], and are the most prevalent psychiatric disorders [2]. Their symptoms are: sweating, tremors, cold shivers, tachycardia, poor mental state, hyperventilation, in addition to difficulty with concentration, emotional instability, compromised sleep quality and difficulties with performing daily tasks [3]. They are classified into: panic attack, agoraphobia, generalized anxiety disorder (GAD), social phobia, specific phobia, separation anxiety disorder [4].

An American census conducted between 2019 and 2020, before and during the Covid19 pandemic, demonstrated that the rate of prevalence of anxiety increased three times more in this population, rising from 8.2% to 29.4%, with a discrete reduction between April and May 2020 [5]. Relative to gender, in women the prevalence was approximately double the rate in comparison with men [2, 4]. Furthermore, the World Health Organization (WHO) released its major global review of mental health around the world in 2022, showing that in 2019, an estimated 970 million people were living with some type of mental disorder, anxiety disorders (31.0%) and depressive disorders (28.9%) were the most prevalent for both genders [6].

ADs are brain disturbances in which various heterogeneous pathogenic mechanisms are expressed [7]. Their neurobiology is complex, resulting from the interaction of various psychological, environmental and biological factors. They are characterized by a variety of factors related to neuroendocrinology, neurotransmitter circuits and neuroanatomic changes, aggravated by the high degree of interconnectivity between the circuits of the limbic system, brainstem and cortical areas of the brain, which may be of environmental or genetic origin [8].

The physiopathology of anxiety disorders, on which studies have been limited to laboratory studies and experiments with animals in the last few decades, is similar to that of the psychiatric disorder most studied in the area of psychoimmunology, the major depressive disorder, of which the biological mechanisms most recently studied are: neuroinflammation and the immune kynurenine pathway [7].

Exposure to stress, one of the main risk factors for psychiatric diseases, may cause neuroinflammation and have repercussions on neurogenesis, leading to damage in brain plasticity, compromising psychic functions such as learning and memory [9], and inducing anxious behaviors [10].

Studies have hypothesized that through the presence of inflammatory cytokines, neuroinflammation contributes to deviation of the route of production of the neurotransmitter serotonin. This begins from its main precursor amino acid, tryptophan, by the presence of the enzyme 2,3 dioxxygenase, leading to the production of kynurenine, a compound that can be converted into the neurotoxic metabolite: quinolinic acid. This quinolinic acid activates the receptors of glutamate, an excitatory neurotransmitter, stimulates its release and blocks its re-uptake by the astrocytes, contributing to it not becoming excessive within and outside of the synapse, increasing the glutamate excitotoxicity, diminishing the production of the brain derived neurotrophic factor (BDNF) [9].

BDNF is an abundant neurotrophin in the brain, and among its other functions, it is responsible for cerebral plasticity and neurogenesis, the process whereby the neurons are generated from progenitors for integration into the neuronal network [11].

Further to the neurobiology of ADs, the increase in activity in regions of the brain that process emotion, in patients who have anxiety disorder, this may result from glutamate excess [8]. On diminishing the levels of BDNF,

this excess may in turn affect the integrity of the neuronal system, by compromising brain neurogenesis [10].

According to the WHO, approximately half of the cases of AD are diagnosed, 1/3 receive medication treatment, 1/5 (20.6%) seek the help of health services, so that 23.2% receive no treatment whatsoever. Of the others, 30.8% receive medication treatment only, 19.6% receive psychological treatment only, and 26.5 were treated with medication and psychotherapy [4]. At least 1/3 of the patients with anxiety disorders do not respond to pharmacological treatment, and as yet there is no explanation for justifying the reason why some patients respond well, and others do not [12].

Regarding treatment, when compared with medication therapy, physical exercise is considered an alternative for anxiety disorders. Not only does it cost less and have fewer adverse side effects, but it may be associated with the rise in BDNF levels [13]. A research with lifestyle intervention (diet, physical exercise, and change in behavior), showed considerable benefits in cases of moderate to severe anxiety [14].

The aim of this research was to analyze the relationship between AD and BDNF levels, with the intention of contributing to a better understanding of the relations between compromised neuroanatomic structures and the changes in psychic functions in ADs.

Methodology

This was an integrative review of the literature, with articles being selected among scientific publications in the [Virtual Library on Health](#) (Biblioteca Virtual em Saúde - BVS) and [PubMed](#). The inclusion criteria were as follows; 1) publications in the electronic databases of: [PubMed](#), [SciELO](#) and [LILACS](#), between 2008 and 2018, using the following descriptors: Anxiety disorders (transtornos da ansiedade) and BDNF. Analysis were performed in two stages, according to the PRISMA Flow Diagram [[Figure 1](#)] [15].

In the first stage, the exclusion criteria were: 1) text written in a language other than English and Portuguese, 2) did not approach the subject of anxiety disorders (AD) and BDNF, including polymorphisms related to the BDNF gene.

The exclusion criteria applied in the second stage were: 1) articles with an approach to the relationship between BDNF, including polymorphisms related to the BDNF gene, and AD, in accordance with the diagnosis of DSM

V, 2) review articles and 3) absence of consensus among all the researchers about the selection of the article.

Results and Discussion

Initially, 698 articles in English were selected, in the period from 2000 to 2018. These went through two stages of analysis, according to the Flow Diagram PRISMA [Figure 1] [15]. Initially, 10 duplicated articles were removed. At this stage, the articles were divided among the researchers, who made their selections independently. After applying the exclusion criteria, 101 articles remained for analysis.

After this, in the first stage of exclusion, the following were removed: review articles, those that did not approach the relations between levels of BDNF and TA, including polymorphism, and those with absence of consensus about the relations between BDNF and AD among all the researchers, who had analyzed them independently, after having read the complete text. In cases in which there was disagreement, the researchers decided on exclusion of the article. The 28 final articles generated data for filling out [Table 1](#), [Table 2](#) and [Table 3](#). Due to the type of study design chosen, there was no need to approach ethical aspects.

The neurotrophic hypothesis is applicable, particularly to depression, however, the relationship of BDNF with AD has been approached in up to date researches, both in rodents and human beings. In addition to having similar physiopathological characteristics, ADs and depression share a genetic base in various subtypes, therefore, contributing to the emergence of studies about the neurotrophic hypothesis for the physiopathology of AD [16].

According to Carlino et al. [17], BDNF is not a biomarker of anxiety, but its serum levels have been found to be reduced to a greater extent in women with generalized anxiety disorder, than in men, and have been specifically correlated with gender. In a case-control study, conducted with 775 persons, the results did not confirm the hypothesis that the serum concentration of BDNF would be reduced in patients with anxiety disorder, when compared with controls, suggesting that it was improbable that BDNF would be involved in the physiopathology of ADs. The specific finding of gender, showing low levels of BDNF only in women with anxiety disorder may suggest that BDNF was related with the physiopathology of anxiety, only in women, not in men. The findings also suggested that there was no relationship between the levels of BDNF and severity of the anxiety [18].

Changes in the BDNF levels may be related to the reduction in functionality of the hippocampus, pointing towards the risk of developing anxiety disorders [19], as well greater severity of depressive and anxious symptoms in patients dependent on nicotine [20], worse conditions of anxiety in individuals with early onset panic disorders [21], and the occurrence of anxiety in elderly women [22]. One case-control study showed that the BDNF levels were elevated in the lymphocytes of patients with GAD, and so were the levels of BDNF RNAm expression, when compared with those of healthy controls [23].

Evaluation of the plasma levels of BDNF, in a research with 129 adolescents and 17 rats, demonstrated that exposure to early stress was a risk factor for AD, and had repercussions on higher levels of BDNF in adult life, in comparison with the other group, without exposure to stress. Moreover, maternal overprotection and control behaviors in the human sample, appeared to be related to increased peripheral levels of BDNF and AD in the adult stage [24].

In addition to the serum levels of BDNF, studies have evaluated the correlation between levels of BDNF polymorphism and AD. One study with this objective comparing cases of GAD with healthy controls, showed that there was no significant difference in frequency of BDNF polymorphisms in cases with GAD, in spite of the plasma levels of BDNF being significantly reduced in these cases [25].

According to Montag et al. [26], the BDNF polymorphism may suggest a predisposition to developing GAD, in addition to selectively influencing specific facets of anxious behavior. Individuals with anxiety comorbidity had a higher proportion of BDNF polymorphisms, and higher level of neuroticism for avoiding damage than all the other groups [27].

A cross-sectional study showed that BDNF polymorphism was also associated with greater trait anxiety [28], and reduction in stability of behavioral inhibition from 3 to 6 years of age [29], seen in another study. In an experimental prospective cohort study with rats, association was demonstrated between early exposure to vaporized ethanol, BDNF polymorphism and reduction in volume of some regions of the hippocampus [30].

In an experimental study and another with humans, it was observed that rats exposed to stressful situations: maternal separation, contention and

combinations of the two conditions, showed significant depressive and anxious behaviors, when compared with controls. There was association between anxiety disorder and BDNF polymorphisms, which could indicate the psychic vulnerability of individuals with this genetic variant. This discovery, in conjunction with the association between BDNF polymorphisms and anxiety disorder, emphasized the role of BDNF in this pathology [31].

Concerning the neurobiology of AD, the volume of some structures, specifically the dorsal portion of the dorsal-lateral cortex and insula, undergo modulation by the BDNF polymorphism, which is distinctly observed when anxious adolescents are compared with healthy individuals, reinforcing the neurotrophic hypothesis of the physiopathology of AD. The modulation of these regions by BDNF suggests that these structures could have greater sensitivity to the action of BDNF in adolescence, and could present risk for AD [32].

An experimental study with 15 rodents demonstrated association between AD and BDNF levels, with repercussions on facilitated associative learning. In this study, not only was the reduction of BDNF in the hippocampus of rodents observed to be related to the acquisition of associative learning, but also that the administration of BDNF in the hippocampus of rats contributed to its occurrence [33].

In a prospective cohort with 45 pregnant female rats, submitted to stress (witnessing the social defeat of their partners), they showed anxious behaviors up to three weeks postpartum. This could be related to changes in BDNF expression in the hippocampus, prefrontal medial cortex and amygdala, with the expression being reduced in the hippocampus, and increased in the amygdala [34].

Furthermore, in a prospective cohort with 45 isolated female rats, significantly increased BDNF expression in the cerebral cortex was shown, when compared with the control, in addition to anxious behavior [35].

From this perspective, studies have pointed out that the Val/Met genotype represented an independent risk factor for AD in childhood and adolescence, reinforcing the hypothesis that BDNF has neurobiological characteristics that have influence in the genesis of anxiety [36]. Furthermore, Lau et al. [16], in a study comparing healthy adolescents with individuals with AD, considered the activation of brain structures such

as the amygdala and hippocampus, as findings in BDNF polymorphism carriers, also considering that the activation was modulated by BDNF. Therefore, it was concluded that lower levels of BDNF were associated with the expression of AD symptoms during adolescence, possibly also playing a role in the long term effects on individuals.

A case-control study with 93 participants, showed that BDNF polymorphism carrier patients with prostate cancer, were at greater risk for hypercortisolism secondary to stressful experiences than patients who did not have the allele, data that could be important for preventing GAD in men with prostate cancer [37]. Further to the relationship between stress and BDNF, in an experimental prospective cohort, autism induced by stress and anxious behaviors caused by neonatal isolation could be hypothesized, by means of regulating the expression of BDNF RNAm [38].

According to the studies described above, when considering that both plasma levels of BDNF and BDNF polymorphism could be altered in AD, it would be plausible to question whether both, although unspecific, could be biomarkers of AD. A population based cross-sectional study has suggested that BDNF could be characterized as a biologic marker associated with AD, to the extent to which it may be involved in the neurobiology of GAD, and considering the association of the BDNF polymorphism as risk factor for the occurrence of the disease [39].

A research conducted with pregnant women with GAD, showed reduced serum levels of BDNF when compared with healthy women, which explained the reduced fetal levels of BDNF in the umbilical cord. The duration of maternal GAD showed a significant effect on the reduction of fetal BDNF levels, however, without association with the severity of the anxious symptoms [40].

In spite of the increase in BDNF representing a reflection of normalization of the physiopathology of the disease, the mechanisms of BDNF, isolated, could not be pointed out as being responsible for the response to antidepressants. However, considering that a study with Duloxetine increased the plasma levels of BDNF in patients with GAD, this suggests that the increase in the levels of BDNF reflected the effect of the medication therapy [41].

Regarding neuromodulation treatment for GAD, with rTMS (bilateral low-frequency transcranial repetitive magnetic stimulation) on the dorsolateral

prefrontal cortex, at least partially involves the interaction of BDNF and 5-HT in the brain [42].

Conclusion

The studies were observed to point towards the relationship between levels of BDNF and AD, with change in the levels of this neurotrophin in both humans and animals. However, further studies are necessary to present evidence of this association which, if proved, could contribute to action of prevention of AD in the services of mental health care, from primary prevention, including improvements in lifestyle, through to secondary prevention, with early diagnosis, considering the possibility of validating the use of BDNF as a possible, although unspecific, biomarker for mental health.

Acknowledgment

For the financing by FUNADESP (Fundação Nacional para o Desenvolvimento do Ensino Particular) - National Foundation for the Development of Private Schooling.

References

1. American Psychiatric Association. Manual diagnóstico e estatístico de transtornos mentais: DSM-5. 5. ed. Porto Alegre: Artmed; 2014.
2. Lépine JP. The epidemiology of anxiety disorders: prevalence and societal costs. *J Clin Psychiatry*. 2002;63 Suppl 14:4-8. PMID:12562112
3. Hu S, Tucker L, Wu C, Yang L. Beneficial effects of exercise on depression and anxiety during the covid-19 pandemic: a narrative review. *Front Psychiatry*. 2020;11:587557. <https://doi.org/10.3389/fpsy.2020.587557> - PMID:33329133
PMCID:PMC7671962
4. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. *Dialogues Clin Neurosci*. 2015;17(3):327-35. <https://doi.org/10.31887/dcns.2015.17.3/bbandelow> PMID:26487813 - PMCID:PMC4610617
5. Twenge JM, Joiner TE. U.S. Census Bureau-assessed prevalence of anxiety and depressive symptoms in 2019 and during the 2020 covid-19 pandemic. *Depress Anxiety*. 2020;37(10):954-6. <https://doi.org/10.1002/da.23077> - PMID:32667081
PMCID:PMC7405486

6. World Health Organization. World mental health report: transforming mental health for all. Geneva: World Health Organization; 2022.
<https://www.who.int/publications/i/item/9789240049338>
7. Kim YK, Jeon SW. Neuroinflammation and the immune-kynurenine pathway in anxiety disorders. *Curr Neuropharmacol*. 2018;16(5):574-82.
<https://doi.org/10.2174/1570159x15666170913110426>
PMID:28901278 - PMCID:PMC5997870
8. Martin EI, Ressler KJ, Binder E, Nemeroff CB. The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. *Psychiatr Clin North Am*. 2009;32(3):549-75. <https://doi.org/10.1016/j.psc.2009.05.004>
PMID:19716990 - PMCID:PMC3684250
9. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol*. 2016;16(1):22-34. <https://doi.org/10.1038/nri.2015.5>
PMID:26711676 - PMCID:PMC5542678
10. Chiba S, Numakawa T, Ninomiya M, Richards MC, Wakabayashi C, Kunugi H. Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012;39(1):112-9.
<https://doi.org/10.1016/j.pnpbp.2012.05.018> - PMID:22664354
11. Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. *Front Cell Neurosci*. 2014;8:430.
<https://doi.org/10.3389/fncel.2014.00430> - PMID:25565964
PMCID:PMC4273623
12. Maron E, Nutt D. Biological predictors of pharmacological therapy in anxiety disorders. *Dialogues Clin Neurosci*. 2015;17(3):305-17.
<https://doi.org/10.31887/dcns.2015.17.3/emaron> - PMID:26487811
PMCID:PMC4610615

13. Latsko MS, Gilman TL, Matt LM, Nylocks KM, Coifman KG, Jasnow AM. A novel interaction between tryptophan hydroxylase 2 (TPH2) gene polymorphism (rs4570625) and BDNF Val66Met predicts a high-risk emotional phenotype in healthy subjects. *PLoS One*. 2016;11(10):e0162585.
<https://doi.org/10.1371/journal.pone.0162585> - PMID:27695066
PMCID:PMC5047464
14. Null G, Pennesi L. Diet and lifestyle intervention on chronic moderate to severe depression and anxiety and other chronic conditions. *Complement Ther Clin Pract*. 2017;29:189-93.
<https://doi.org/10.1016/j.ctcp.2017.09.007> - PMID:29122259
15. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
<https://doi.org/10.1371/journal.pmed.1000097> - PMID:19621072
PMCID:PMC2707599
16. Lau JY, Goldman D, Buzas B, Hodgkinson C, Leibenluft E, Nelson E, Sankin L, Pine DS, Ernst M. BDNF gene polymorphism (Val66Met) predicts amygdala and anterior hippocampus responses to emotional faces in anxious and depressed adolescents. *Neuroimage*. 2010;53(3):952-61.
<https://doi.org/10.1016/j.neuroimage.2009.11.026> PMID:19931400
PMCID:PMC2888869
17. Carlino D, Francavilla R, Baj G, Kulak K, d'Adamo P, Ulivi S, Cappellani S, Gasparini P, Tongiorgi E. Brain-derived neurotrophic factor serum levels in genetically isolated populations: gender-specific association with anxiety disorder subtypes but not with anxiety levels or Val66Met polymorphism. *PeerJ*. 2015;3:e1252.
<https://doi.org/10.7717/peerj.1252> - PMID:26539329
PMCID:PMC4631459
18. Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Prickaerts J, Oude Voshaar RC, Elzinga BM. Gender specific associations of serum levels of brain-derived neurotrophic factor in anxiety. *World J Biol Psychiatry*. 2012;13(7):535-43.
<https://doi.org/10.3109/15622975.2011.587892> - PMID:21888560
19. Andreatta M, Neueder D, Genheimer H, Schiele MA, Schartner C, Deckert J, Domschke K, Reif A, Wieser MJ, Pauli P. Human BDNF

rs6265 polymorphism as a mediator for the generalization of contextual anxiety. *J Neurosci Res.* 2019;97(3):300-12.
<https://doi.org/10.1002/jnr.24345> - PMID:30402941

20. Jamal M, Van der Does W, Penninx BW. Effect of variation in BDNF Val(66)Met polymorphism, smoking, and nicotine dependence on symptom severity of depressive and anxiety disorders. *Drug Alcohol Depend.* 2015;148:150-7.
<https://doi.org/10.1016/j.drugalcdep.2014.12.032> PMID:25618300
21. Konishi Y, Tanii H, Otowa T, Sasaki T, Kaiya H, Okada M, Okazaki Y. The association of BDNF Val66Met polymorphism with trait anxiety in panic disorder. *J Neuropsychiatry Clin Neurosci.* 2014;26(4):344-51.
<https://doi.org/10.1176/appi.neuropsych.11120359>
PMID:26037856
22. Chagnon YC, Potvin O, Hudon C, Prévaille M. DNA methylation and single nucleotide variants in the brain-derived neurotrophic factor (BDNF) and oxytocin receptor (OXTR) genes are associated with anxiety/depression in older women. *Front Genet.* 2015;6:230.
<https://doi.org/10.3389/fgene.2015.00230> - PMID:26175754
PMCID:PMC4485183
23. Pallanti S, Tofani T, Zanardelli M, Di Cesare Mannelli L, Ghelardini C. BDNF and artemin are increased in drug-naïve non-depressed GAD patients: preliminary data. *Int J Psychiatry Clin Pract.* 2014;18(4):255-60.
<https://doi.org/10.3109/13651501.2014.940051> - PMID:24994477
24. Dalle Molle R, Portella AK, Goldani MZ, Kapczinski FP, Leistner-Segal S, Salum GA, Manfro GG, Silveira PP. Associations between parenting behavior and anxiety in a rodent model and a clinical sample: relationship to peripheral BDNF levels. *Transl Psychiatry.* 2012;2:e195. <https://doi.org/10.1038/tp.2012.126> PMID:23168995
PMCID:PMC3565759
25. Wang Y, Zhang H, Li Y, Wang Z, Fan Q, Yu S, Lin Z, Xiao Z. BDNF Val66Met polymorphism and plasma levels in Chinese Han population with obsessive-compulsive disorder and generalized anxiety disorder. *J Affect Disord.* 2015;186:7-12.
<https://doi.org/10.1016/j.jad.2015.07.023> - PMID:26209750

26. Montag C, Reuter M, Newport B, Elger C, Weber B. The BDNF Val66Met polymorphism affects amygdala activity in response to emotional stimuli: evidence from a genetic imaging study. *Neuroimage*. 2008;42(4):1554-9.
<https://doi.org/10.1016/j.neuroimage.2008.06.008>
PMID:18603005
27. Enoch MA, White KV, Waheed J, Goldman D. Neurophysiological and genetic distinctions between pure and comorbid anxiety disorders. *Depress Anxiety*. 2008;25(5):383-92.
<https://doi.org/10.1002/da.20378> - PMID:17941097
28. Montag C, Basten U, Stelzel C, Fiebach CJ, Reuter M. The BDNF Val66Met polymorphism and anxiety: support for animal knock-in studies from a genetic association study in humans. *Psychiatry Res*. 2010;179(1):86-90.
<https://doi.org/10.1016/j.psychres.2008.08.005> - PMID:20478625
29. Vandermeer MRJ, Sheikh HI, Singh SS, Klein DN, Olinio TM, Dyson MW, Bufferd SJ, Hayden EP. The BDNF gene val66met polymorphism and behavioral inhibition in early childhood. *Soc Dev*. 2018;27(3):543-54. <https://doi.org/10.1111/sode.12292>
PMID:30245555 - PMCID:PMC6142175
30. Bird CW, Baculis BC, Mayfield JJ, Chavez GJ, Ontiveros T, Paine DJ, Marks AJ, Gonzales AL, Ron D, Valenzuela CF. The brain-derived neurotrophic factor VAL68MET polymorphism modulates how developmental ethanol exposure impacts the hippocampus. *Genes Brain Behav*. 2019;18(3):e12484.
<https://doi.org/10.1111/gbb.12484> - PMID:29691979
PMCID:PMC6291361
31. McGregor NW, Dimatelis JJ, Van Zyl PJ, Hemmings SMJ, Kinnear C, Russell VA, Stein DJ, Lochner C. A translational approach to the genetics of anxiety disorders. *Behav Brain Res*. 2018;341:91-7.
<https://doi.org/10.1016/j.bbr.2017.12.030> - PMID:29288745
32. Mueller SC, Aouidad A, Gorodetsky E, Goldman D, Pine DS, Ernst M. Gray matter volume in adolescent anxiety: an impact of the brain-derived neurotrophic factor Val(66)Met polymorphism? *J Am Acad Child Adolesc Psychiatry*. 2013;52(2):184-95.
<https://doi.org/10.1016/j.jaac.2012.11.016> - PMID:23357445
PMCID:PMC3570270

33. Janke KL, Cominski TP, Kuzhikandathil EV, Servatius RJ, Pang KC. Investigating the role of hippocampal BDNF in anxiety vulnerability using classical eyeblink conditioning. *Front Psychiatry*. 2015;6:106. <https://doi.org/10.3389/fpsy.2015.00106> PMID:26257661 - PMCID:PMC4513557
34. Miao Z, Mao F, Liang J, Szyf M, Wang Y, Sun ZS. Anxiety-related behaviours associated with microRNA-206-3p and BDNF expression in pregnant female mice following psychological social stress. *Mol Neurobiol*. 2018;55(2):1097-111. <https://doi.org/10.1007/s12035-016-0378-1> - PMID:28092086
35. Kumari A, Singh P, Baghel MS, Thakur MK. Social isolation mediated anxiety like behavior is associated with enhanced expression and regulation of BDNF in the female mouse brain. *Physiol Behav*. 2016;158:34-42. <https://doi.org/10.1016/j.physbeh.2016.02.032> - PMID:26921097
36. Tocchetto A, Salum GA, Blaya C, Teche S, Isolan L, Bortoluzzi A, Rebelo e Silva R, Becker JA, Bianchin MM, Rohde LA, Leistner-Segal S, Manfro GG. Evidence of association between Val66Met polymorphism at BDNF gene and anxiety disorders in a community sample of children and adolescents. *Neurosci Lett*. 2011;502(3):197-200. <https://doi.org/10.1016/j.neulet.2011.07.044> - PMID:21839144
37. Sharpley CF, Christie DRH, Bitsika V, Andronicos NM, Agnew LL, Richards TM, McMillan ME. Comparing a genetic and a psychological factor as correlates of anxiety, depression, and chronic stress in men with prostate cancer. *Support Care Cancer*. 2018;26(9):3195-200. <https://doi.org/10.1007/s00520-018-4183-4> - PMID:29603029
38. Bahi A. Sustained lentiviral-mediated overexpression of microRNA124a in the dentate gyrus exacerbates anxiety- and autism-like behaviors associated with neonatal isolation in rats. *Behav Brain Res*. 2016;311:298-308. <https://doi.org/10.1016/j.bbr.2016.05.033> - PMID:27211062
39. Moreira FP, Fabião JD, Bittencourt G, Wiener CD, Jansen K, Oses JP, Quevedo LA, Souza LDM, Crispim D, Portela LV, Pinheiro RT, Lara DR, Kaster MP, Silva RA, Ghisleni G. The met allele of BDNF Val66Met polymorphism is associated with increased BDNF levels in

generalized anxiety disorder. *Psychiatr Genet*. 2015;25(5):201-7.
<https://doi.org/10.1097/ypg.000000000000097> PMID:26110341

40. Uguz F, Sonmez EO, Sahingoz M, Gokmen Z, Basaran M, Gezginc K, Sonmez G, Kaya N, Erdem SS, Cicekler H, Tasyurek E. Maternal generalized anxiety disorder during pregnancy and fetal brain development: a comparative study on cord blood brain-derived neurotrophic factor levels. *J Psychosom Res*. 2013;75(4):346-50.
<https://doi.org/10.1016/j.jpsychores.2013.04.010> PMID:24119941
41. Ball S, Marangell LB, Lipsius S, Russell JM. Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013;43:217-21. <https://doi.org/10.1016/j.pnpbp.2013.01.002> PMID:23313564
42. Lu R, Zhang C, Liu Y, Wang L, Chen X, Zhou X. The effect of bilateral low-frequency rTMS over dorsolateral prefrontal cortex on serum brain-derived neurotropic factor and serotonin in patients with generalized anxiety disorder. *Neurosci Lett*. 2018;684:67-71.
<https://doi.org/10.1016/j.neulet.2018.07.008> - PMID:30008380
43. Ernst C, Marshall CR, Shen Y, Metcalfe K, Rosenfeld J, Hodge JC, Torres A, Blumenthal I, Chiang C, Pillalamarri V, Crapper L, Diallo AB, Ruderfer D, Pereira S, Sklar P, Purcell S, Wildin RS, Spencer AC, Quade BF, Harris DJ, Lemyre E, Wu B-L, Stavropoulos DJ, Geraghty MT, Shaffer LG, Morton CC, Scherer SW, Gusella JF, Talkowski, M. E. Highly penetrant alterations of a critical region including BDNF in human psychopathology and obesity. *Arch Gen Psychiatry*. 2012;69(12):1238-1246.
<https://doi.org/10.1001/archgenpsychiatry.2012.660>

↑ **Table 01.** Results of the integrative review of the literature of studies with humans

	Author, year	Design	N	Results	Conclusions
1.	Andreatt aet al., 2019 [19]	Case- Control	65	In the experiment with humans, with prior genotype analysis, in a virtual environment with predictable shock stimulus (CTX+), another without shock stimulus (CTX-), and one with unpredictable stimulus (G-CTX), considered a mixture between the two previous types, the responses were analyzed. CTX+ was classified as being more excitant, anxiogenic and caused potentiated responses.	The BDNF polymorphism did not affect... ...contextual learning and its generalization at a verbal level. Individuals with Met are characterized by rapid discriminative contextual learning and a tendency towards generalizing anxiety responses to ambiguous contexts. This learning may be related to the reduction in functionality of the hippocampus, and the risk of individuals with Met developing anxiety disorders.

2.	Carlino et al., 2015 [17]	Cross-sectional	672	<p>There was no significant correlation between the levels and severity of AD, reduction in neurotrophic activity (serum level of BDNF) or associated genetic polymorphism. There was evidence of a significant reduction in serum BDNF in women with GAD, and in men with Specific Phobias. There were indications of low heritability and absence of any impact of Val66Met polymorphism in the circulating concentrations of BDNF.</p>	<p>BDNF is not a general biomarker of anxiety, but the serum levels of BDNF were specifically correlated to gender with the subtypes of Anxiety Disorders.</p>
3.	Jamal et al., 2015 [20]	Cross-sectional	127 1	<p>Among individuals with BDNF Val carrier patients, those who were nicotine dependent smokers had more severe symptoms of depression than the other three groups (smokers not dependent on nicotine, and non-smokers) who also had the polymorphism.</p>	<p>The study suggested that genetic differences maybe crucial for the worst behavioral results in nicotine users, and that BDNF Val (66) polymorphism carrier patients could benefit their mental health to a greater extent by quitting smoking.</p>

4.	Konishi et al., 2014 [21]	Cross-sectional	252	In the Group with Early Onset of Panic Disorder (<30 years), the State-Trait Anxiety Inventory (STAI) Score was higher in carriers of the BDNF Met/Met polymorphism and tended to be lower in those with Val/Val or Val/Met. The high score was also found in the Val/Val genotype of the control group (healthy individuals).	The genotype BDNF Met/Met could increase the characteristics of anxiety in early onset Panic Disorder.
5.	Chagnon et al., 2015 [22]	Cross-sectional	43	The higher [level of] DNA methylation of BDNF was observed in individuals with anxiety/depression in comparison with individuals in the Control Group. The difference was greater for BDNF genotype CT rs626 carriers, compared with those with genotype CC.	The results suggested that DNA methylation interaction with the Single Nucleotide Variants (SNVs) in BDNF are associated with the occurrence of anxiety / depression in elderly women.



6.	Mueller et al., 2013 [32]	Cross-sectional	39	The dorsal anterior cingulate cortex (dACC), hippocampus, amygdala and insula, main brain structures related to Anxiety Disorder (AD) were found to have differentiated volumes in Groups of adolescents with AD. These changes vary according to the BDNF genotype.	The volume of some structures, specifically the dorsal portion of the dorsal-lateral cortex and insula undergo modulation by BDNF-Val polymorphism. This reinforces the neurotrophic hypothesis of the physiopathology of AD. These structures may be more sensitive to the action of BDNF in adolescence, so that the risk for development of AD may be identified.
7.	Tocchetto et al., 2011 [36]	Case-Control	240	In analysis of the BDNF gene, by means of saliva samples of children and adolescents with and without Anxiety Disorder (AD), a considerable association was found of being an Met allele carrier of BDNF, with greater chance of anxiety disorders.	The Val/Met genotype represents an independent risk factor for AD in childhood and adolescence, reinforcing the neurotrophic hypothesis of the physiopathology of AD, which ratifies the hypothesis that BDNF may be related to the development of early onset AD.

8.	Lau et al., 2010 [16]	Case-Control	58	<p>In the investigation of association between the BDNF genotype and the amygdala-hippocampal responses to emotional stimuli in adolescents with AD and/or major depressive disorder in comparison with healthy adolescents (Control Group). Evidence was shown of greater activations in the regions of the amygdala and anterior hippocampus in a higher number of patients with AD.</p>	<p>In the comparison between cases and controls, there was greater activation of brain structures such as the amygdala and hippocampus in response to expressions in the cases of Met variant carriers. This activation is modulated by BDNF. Lower levels of BDNF were associated with the expression of symptoms during the period of adolescence, and also played a role in the long term effects, which culminated in AD.</p>
9.	Enoch et al., 2008 [27]	Cross-sectional	249	<p>Individuals with anxiety comorbidity had a higher proportion of alleles COMT Met158 and BDNF Met66 ($P = 0,009$), and a higher level of neuroticism to avoid damage, ($P < 0.0005$) than all the other groups.</p>	<p>There may be two vulnerability factors for AD with different genetic susceptibility: (a) increased attention and better memory of work with slightly elevated anxiety neuroticism and (b) lower level of attention and working memory with higher level of anxiety - neuroticism. This refinement of the anxiety phenotype may have implications for therapeutic interventions.</p>



10	Montag et al., 2008 [26]	Experimental	37	The 66Met variant carriers showed a stronger activation of the amygdala in the right hemisphere in response to emotional stimuli in comparison with that to neutral stimuli.	The results of this study added to the growing literature, showing that the BDNF 66Met polymorphism, which is associated with greater intensity of anxious manifestations.
11	Moreira et al., 2015 [39]	Cross-sectional	816	The study showed a significant association between the Met and GAD allele. The serum levels of BDNF, however, did not diverge according to the diagnosis or distribution of the genotype. There were differences in the serum levels of BDNF in patients with GAD, according to the allele, with the allele Met being associated with higher levels of BDNF in comparison with Val/Val, after adjustment of variables.	The study suggested that BDNF could be characterized as a biological marker associated with AD, to the extent to which it could be involved in the neurobiology of GAD; and considering the association of the allele Met as a risk factor for the occurrence of disease.

12	ERNST, C et al. 2012 [43]	Case-Control	67 255	Five individuals with deletions that covered to entire BDNF gene were identified in the study. This genic region was not changed in the control individuals or in cases diagnosed as being without developmental abnormalities.	Hemizygosis (exclusion of alleles) from the BDNF region contributes to variable psychiatric phenotypes, including those at the AD, behavioral and mood levels.
13	Uguz et al., 2013 [40]	Cross-sectional	44	Newborns, children of healthy mothers, showed approximately two times more concentration of BDNF in comparison with children of mothers who had GAD. The duration of GAD during pregnancy was the only variable that correlated with the levels of BDNF in the umbilical cord.	The duration of maternal GAD has a significant effect on the reduction of fetal BDNF levels, while the severity of anxious symptoms did not interfere.
14	Wang et al., 2015 [25]	Case-Control	355	Patients who had GAD or Compulsive Obsessive Disorder (COD) had significantly reduced plasma levels of BDNF, when compared with healthy control patients.	BDNF was involved in the physiopathology of mental disorders, not only in COD, but also in GAD. The patients with COD and GAD showed lower plasma levels of BDNF in comparison with healthy controls.

15	Ball et al., 2013 [41]	Randomized Clinical Trial	210	Patients who had GAD were treated with Duloxetine, whereas those treated with placebo obtained a significant mean increase in the BDNF levels from the beginning to end of the trial.	Treatment with Duloxetine increased the plasma levels of BDNF in patients with GAD. The studies suggested that the increase in BDNF reflected an effect of the antidepressant therapy. In spite of the increase in BDNF representing a normalization reflex of the physiopathology of the disease, the mechanisms of BDNF alone, could not be pointed out as being responsible for the therapeutic response.
16	Vandermeer et al., 2018 [29]	Cohort	476	This study showed that individuals with at least one allele met had better stability of behavioral inhibition at the age from 3 to 6 than individuals without the met variant.	The BDNF Val66Met single nucleotide polymorphism (SNP) was associated with reduced stability of behavioral inhibition from 3 to 6 years of age.



17	Lu et al., 2018 [42]	Clinical Trial	35	<p>The overall score on the HAM-A scale post-treatment with bilateral low-frequency repetitive transcranial magnetic stimulation on the dorsolateral prefrontal cortex for GAD, was significantly reduced when compared with the pre-treatment score. This suggested a significant reduction in the anxious symptoms, and significant increase in the serum concentrations of BDNF and 5-HT. The results showed a positive correlation between the increase in BDNF concentration with an increase in 5-HT concentration, and negative correlation between the serum concentrations of BDNF and 5-HT in relation to the score on the HAM-A scale.</p>	<p>The results suggested that the potential therapeutic mechanisms of bilateral low-frequency repetitive transcranial magnetic stimulation on the dorsolateral prefrontal cortex for GAD, at least partly, involved the interaction of BDNF and 5-HT in the brain.</p>
----	----------------------	----------------	----	---	--



18	Montag et al., 2010 [26]	Cross-sectional Study	610	<p>Patients who were homozygous for the BDNF 66Met Allele showed a significantly increased Temperament and Character Inventory (TCI) score for the facets related to the anxious personality in the construct of Harm Avoidance: Anticipatory worry and fear of uncertainty, when compared with allele Val66 carriers.</p>	<p>The impact of the BDNF Val66Met variant may represent a link to predisposition for developing GAD, and must, therefore, selectively influence specific facets of anxious behavior.</p>
19	Pallanti et al., 2014 [23]	Case-Control	24	<p>PCR Analysis showed that the BDNF measures were elevated in the lymphocytes of patients with GAD, when compared with those of healthy controls. The levels of BDNF RNAm expression were significantly increased in patients with GAD, when compared with healthy controls.</p>	<p>There was a considerable increase in the BDNF levels in patients with GAD, when compared with healthy controls.</p>



20	Sharpley et al., 2018 [37]	Case-Control	93	Patients with BDNF Val66Met polymorphism had significantly higher concentrations of salivary cortisol than patients without the allele Met.	Psychological resilience was inversely associated with anxiety and depression, emphasizing the value of the psychological factor in patients with prostate cancer, who could be more vulnerable to the development of anxiety and depression. Patients who had the allele met of the BDNF Val66Met polymorphism were at greater risk for the development of hypercortisolemia as a result of their stressful experiences, than patients who did not have this allele.
----	----------------------------	--------------	----	---	---



21	Molendijk et al., 2012 [18]	Case-Control	775	<p>Patients with anxiety disorder, in general, didn't show significantly different concentrations of BDNF, when compared with controls. Patients of the female sex, with anxiety disorder, showed lower serum concentrations of BDNF than controls of the female sex, and male sex patients. There was no difference in the serum concentrations of BDNF between the different types of anxiety, and there was no association between severity, chronic anxiety or major depressive disturbance and the levels of serum concentration. Age at onset of symptoms showed positive relation to the serum concentration of BDNF in the univariate analysis.</p>	<p>Due to the results, it appears to be improbable that BDNF is involved in the physiopathology of AD <i>per se</i>. The specific finding of gender, showing low levels of BDNF only in women with anxiety disorder, may suggest that BDNF is related to the physiopathology of anxiety only in women, and not in men.</p>
----	-----------------------------	--------------	-----	---	--



Table 2. Results of integrative review of the literature in studies with animals

Author, year	Design	N	Results	Conclusions
1. Janke et al., 2015 [33]	experimental	15	There's indirect relationship between AD and BDNF. The changes inherent to BDNF system have a repercussion on facilitated associative learning.	Not only was it observed that the reduction in BDNF in the hippocampus of rodents was related to the acquisition of associative learning, but also that the administration of BDNF in the hippocampus of rats contributed to its occurrence.

2	Miao et al., 2017 [34]	Prospective Cohort	45	Pregnant female rats, submitted to stress, showed anxious behaviors in propitious tests. In the amygdala of these same females, increased levels of BDNF were found.	The stress caused by witnessing the social defeat of their partners in pregnant female rats may induce anxious behavior up to 3 weeks postpartum. This finding could be correlated to changes in BDNF expression in the hippocampus, medial prefrontal cortex and amygdala of these rats.
3	Kumari et al., 2016 [35]	Prospective Cohort	45	Social isolation caused anxious behavior in female rats. Significantly increased BDNF expression in the cerebral cortex of isolated female rats was observed, when compared with controls.	The anxious behavior caused by social isolation may be mediated by the expression of BDNF.



4	Bahi, 2016 [38]	Prospective Cohort	40	<p>Rats submitted to neonatal isolation as a model of stress showed an increase in miR124a expression, accompanied by suppression of the BDNF RNAm levels in the hippocampus. These findings were accompanied by reduction in social interaction and increase in anxious behavior, when compared with control.</p>	<p>Ectopic expression of miR124a showed efficacy in reducing the social interaction in rats exposed to neonatal isolation. A robust effect of miR124a on anxious behavior was also seen. It was demonstrated that miR124a directly inhibited the expression of BDNF RNAm. These results indicated that in the hippocampus miR124a plays a critical role in the autism spectrum disorder and it could consequently be hypothesized that miR124a could participate in autism induced by stress and anxious behaviors caused by neonatal isolation by means of regulating the expression of BDNF RNAm.</p>
---	-----------------	--------------------	----	--	---



5	Bird et al., 2019 [30]	Prospective Cohort	Total n was not informed and varied in each experiment performed	Early exposure to vaporized ethanol interacted with the BDNF polymorphism to reduce the volume of the hippocampus. But this effect was not static and disappeared as the animal aged. There were no significant changes relative to anxiety.	Genetic variants of BDNF modulate the effect of development in the presence of exposure to ethanol. The findings showed that the interaction between genes and the environment play a determinant role in the behavioral phenotype in individuals with Fetal Alcohol Spectrum Disorder.
---	------------------------	--------------------	--	--	---



Table 03. Results of integrative review of the literature in studies with animals and humans

	Author, year	Design	N	Results	Conclusions
1	Dalle Molle et al., 2012 [24]	Experimental	129 Adolescents, 17 rats	The plasma levels of BDNF in rats demonstrated that early exposure to stress (risk factor for AD), had repercussion on a change in the relationship between mother and pups, and indicated higher levels of BDNF in adult life, in comparison with another group, without exposure.	In addition to the relations of serum levels of BDNF with early stress in rats, similar associations were found in a sample of adolescent human beings, particularly in BDNF Met carriers. Furthermore, maternal overprotection and control behaviors in the human sample, appeared to be related to increased peripheral layers of BDNF an AD in the adult stage.

2	McGregor et al., 2018 [31]	Prospective Cohort (rats) / Case-control (humans)	52 rats 286 humans	The rats exposed to stressful situations, maternal separation, contention and combinations of the two showed significant depressive and anxious behaviors, when compared with unexposed rats. There was association between the diagnosis of anxiety disorder in humans who had: MMP9 (rs3918242) and BDNF (rs6265 e rs10835210) polymorphisms, indicating the vulnerability of individuals with these genetic variants.	The association between BDNF polymorphisms and diagnosis of anxiety disorder in humans, emphasizes the fundamental role of BDNF as moderator of ADs.
---	----------------------------	---	-----------------------	--	--






Figure 1. PRISMA 2009 Flow Diagram

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. <https://doi.org/10.1371/journal.pmed1000097>

For more information, visit www.prisma-statement.org

